Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update

Thomas J. Smith, Kari Bohlke, Gary H. Lyman, Kenneth R. Carson, Jeffrey Crawford, Scott J. Cross, John M. Goldberg, James L. Khatcheressian, Natasha B. Leighl, Cheryl L. Perkins, George Somlo, James L. Wade, Antoinette J. Wozniak, James O. Armitage

Research output: Contribution to journalArticle

283 Citations (Scopus)

Abstract

Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of randomized clinical trials, meta-analyses, and systematic reviews from October 2005 through September 2014. Guideline recommendations were based on the review of the evidence by the Update Committee. Results Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high- dose-intensity chemotherapy in urothelial cancer. The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults. Recommendations Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. Dose-dense regimens that require CSFs should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.

Original languageEnglish (US)
Pages (from-to)3199-3212
Number of pages14
JournalJournal of Clinical Oncology
Volume33
Issue number28
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Colony-Stimulating Factors
Medical Oncology
Practice Guidelines
Intercellular Signaling Peptides and Proteins
Febrile Neutropenia
Drug Therapy
Guidelines
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Meta-Analysis
Lymphoma
Radiotherapy
Randomized Controlled Trials
Clinical Trials
Wounds and Injuries

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., ... Armitage, J. O. (2015). Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. Journal of Clinical Oncology, 33(28), 3199-3212. https://doi.org/10.1200/JCO.2015.62.3488

Recommendations for the use of WBC growth factors : American society of clinical oncology clinical practice guideline update. / Smith, Thomas J.; Bohlke, Kari; Lyman, Gary H.; Carson, Kenneth R.; Crawford, Jeffrey; Cross, Scott J.; Goldberg, John M.; Khatcheressian, James L.; Leighl, Natasha B.; Perkins, Cheryl L.; Somlo, George; Wade, James L.; Wozniak, Antoinette J.; Armitage, James O.

In: Journal of Clinical Oncology, Vol. 33, No. 28, 01.10.2015, p. 3199-3212.

Research output: Contribution to journalArticle

Smith, TJ, Bohlke, K, Lyman, GH, Carson, KR, Crawford, J, Cross, SJ, Goldberg, JM, Khatcheressian, JL, Leighl, NB, Perkins, CL, Somlo, G, Wade, JL, Wozniak, AJ & Armitage, JO 2015, 'Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update', Journal of Clinical Oncology, vol. 33, no. 28, pp. 3199-3212. https://doi.org/10.1200/JCO.2015.62.3488
Smith, Thomas J. ; Bohlke, Kari ; Lyman, Gary H. ; Carson, Kenneth R. ; Crawford, Jeffrey ; Cross, Scott J. ; Goldberg, John M. ; Khatcheressian, James L. ; Leighl, Natasha B. ; Perkins, Cheryl L. ; Somlo, George ; Wade, James L. ; Wozniak, Antoinette J. ; Armitage, James O. / Recommendations for the use of WBC growth factors : American society of clinical oncology clinical practice guideline update. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 28. pp. 3199-3212.
@article{ff5c7dd8d4804a0eb3a6e10cc9214e02,
title = "Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update",
abstract = "Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of randomized clinical trials, meta-analyses, and systematic reviews from October 2005 through September 2014. Guideline recommendations were based on the review of the evidence by the Update Committee. Results Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high- dose-intensity chemotherapy in urothelial cancer. The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults. Recommendations Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia is approximately 20{\%} or higher and no other equally effective and safe regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. Dose-dense regimens that require CSFs should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.",
author = "Smith, {Thomas J.} and Kari Bohlke and Lyman, {Gary H.} and Carson, {Kenneth R.} and Jeffrey Crawford and Cross, {Scott J.} and Goldberg, {John M.} and Khatcheressian, {James L.} and Leighl, {Natasha B.} and Perkins, {Cheryl L.} and George Somlo and Wade, {James L.} and Wozniak, {Antoinette J.} and Armitage, {James O.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1200/JCO.2015.62.3488",
language = "English (US)",
volume = "33",
pages = "3199--3212",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - Recommendations for the use of WBC growth factors

T2 - American society of clinical oncology clinical practice guideline update

AU - Smith, Thomas J.

AU - Bohlke, Kari

AU - Lyman, Gary H.

AU - Carson, Kenneth R.

AU - Crawford, Jeffrey

AU - Cross, Scott J.

AU - Goldberg, John M.

AU - Khatcheressian, James L.

AU - Leighl, Natasha B.

AU - Perkins, Cheryl L.

AU - Somlo, George

AU - Wade, James L.

AU - Wozniak, Antoinette J.

AU - Armitage, James O.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of randomized clinical trials, meta-analyses, and systematic reviews from October 2005 through September 2014. Guideline recommendations were based on the review of the evidence by the Update Committee. Results Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high- dose-intensity chemotherapy in urothelial cancer. The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults. Recommendations Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. Dose-dense regimens that require CSFs should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.

AB - Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical Oncology convened an Update Committee and conducted a systematic review of randomized clinical trials, meta-analyses, and systematic reviews from October 2005 through September 2014. Guideline recommendations were based on the review of the evidence by the Update Committee. Results Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routine dose-dense chemotherapy in lymphoma and in favor of high- dose-intensity chemotherapy in urothelial cancer. The Update Committee did not address recommendations regarding use of CSFs in acute myeloid leukemia or myelodysplastic syndromes in adults. Recommendations Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen. Dose-dense regimens that require CSFs should only be used within an appropriately designed clinical trial or if supported by convincing efficacy data. Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.

UR - http://www.scopus.com/inward/record.url?scp=84944263082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944263082&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.3488

DO - 10.1200/JCO.2015.62.3488

M3 - Article

AN - SCOPUS:84944263082

VL - 33

SP - 3199

EP - 3212

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -